Roger Bate1, Kimberly Hess. 1. American Enterprise Institute, Washington, D.C., USA. rbate@aei.org
Abstract
BACKGROUND: Two major cities in West Africa, Accra, the capital of Ghana, and Lagos, the largest city of Nigeria, have significant problems with substandard pharmaceuticals. Both have actively combated the problem in recent years, particularly by screening products on the market using the Global Pharma Health Fund e.V. Minilab protocol. Random sampling of medicines from the two cities at least twice over the past 30 months allows a tentative assessment of whether improvements in drug quality have occurred. Since intelligence provided by investigators indicates that some counterfeit producers may be adapting products to pass Minilab tests, the results are compared with those from a Raman spectrometer and discrepancies are discussed. METHODS: Between mid-2007 and early-2010, samples of anti-malarial drugs were bought covertly from pharmacies in Lagos on three different occasions (October 2007, December 2008, February 2010), and from pharmacies in Accra on two different occasions (October 2007, February 2010). All samples were tested using the Minilab protocol, which includes disintegration and active ingredient assays as well as visual inspection, and most samples were also tested by Raman spectrometry. RESULTS: In Lagos, the failure rate in the 2010 sampling fell to 29% of the 2007 finding using the Minilab protocol, 53% using Raman spectrometry, and 46% using visual inspection. In Accra, the failure rate in the 2010 sampling fell to 54% of the 2007 finding using the Minilab protocol, 72% using Raman spectrometry, and 90% using visual inspection. CONCLUSIONS: The evidence presented shows that drug quality is probably improving in both cities, especially Lagos, since major reductions of failure rates over time occur with all means of assessment. Many more samples failed when examined by Raman spectrometry than by Minilab protocol. The discrepancy is most likely caused by the two techniques measuring different aspects of the medication and hence the discrepancy may be the natural variation in these techniques. But other explanations are possible and are discussed.
BACKGROUND: Two major cities in West Africa, Accra, the capital of Ghana, and Lagos, the largest city of Nigeria, have significant problems with substandard pharmaceuticals. Both have actively combated the problem in recent years, particularly by screening products on the market using the Global Pharma Health Fund e.V. Minilab protocol. Random sampling of medicines from the two cities at least twice over the past 30 months allows a tentative assessment of whether improvements in drug quality have occurred. Since intelligence provided by investigators indicates that some counterfeit producers may be adapting products to pass Minilab tests, the results are compared with those from a Raman spectrometer and discrepancies are discussed. METHODS: Between mid-2007 and early-2010, samples of anti-malarial drugs were bought covertly from pharmacies in Lagos on three different occasions (October 2007, December 2008, February 2010), and from pharmacies in Accra on two different occasions (October 2007, February 2010). All samples were tested using the Minilab protocol, which includes disintegration and active ingredient assays as well as visual inspection, and most samples were also tested by Raman spectrometry. RESULTS: In Lagos, the failure rate in the 2010 sampling fell to 29% of the 2007 finding using the Minilab protocol, 53% using Raman spectrometry, and 46% using visual inspection. In Accra, the failure rate in the 2010 sampling fell to 54% of the 2007 finding using the Minilab protocol, 72% using Raman spectrometry, and 90% using visual inspection. CONCLUSIONS: The evidence presented shows that drug quality is probably improving in both cities, especially Lagos, since major reductions of failure rates over time occur with all means of assessment. Many more samples failed when examined by Raman spectrometry than by Minilab protocol. The discrepancy is most likely caused by the two techniques measuring different aspects of the medication and hence the discrepancy may be the natural variation in these techniques. But other explanations are possible and are discussed.
Authors: R B Taylor; O Shakoor; R H Behrens; M Everard; A S Low; J Wangboonskul; R G Reid; J A Kolawole Journal: Lancet Date: 2001-06-16 Impact factor: 79.321
Authors: Roger Bate; Kimberly Hess; Richard Tren; Lorraine Mooney; Franklin Cudjoe; Thompson Ayodele; Amir Attaran Journal: Res Rep Trop Med Date: 2012-07-17
Authors: Victor S Pribluda; Adrian Barojas; Arletta Añez; Cecilia G López; Ruth Figueroa; Roxana Herrera; Gladys Nakao; Fernando Ha Nogueira; Gerson A Pianetti; Marinete M Povoa; Giselle Mr Viana; Margarete S Mendonça Gomes; Jose P Escobar; Olga L Muñoz Sierra; Susana P Rendon Norena; Raúl Veloz; Marcy Silva Bravo; Martha R Aldás; Alison Hindssemple; Marilyn Collins; Nicolas Ceron; Karanchand Krishnalall; Malti Adhin; Gustavo Bretas; Nelly Hernandez; Marjorie Mendoza; Abdelkrim Smine; Kennedy Chibwe; Patrick Lukulay; Lawrence Evans Journal: Malar J Date: 2012-06-15 Impact factor: 2.979
Authors: Benjamin J Visser; Janneke Meerveld-Gerrits; Daniëlle Kroon; Judith Mougoula; Rieke Vingerling; Emmanuel Bache; Jimmy Boersma; Michèle van Vugt; Selidji T Agnandji; Harparkash Kaur; Martin P Grobusch Journal: Malar J Date: 2015-07-15 Impact factor: 2.979
Authors: Michael D Green; Dana M Hostetler; Henry Nettey; Isabel Swamidoss; Nicola Ranieri; Paul N Newton Journal: Am J Trop Med Hyg Date: 2015-04-20 Impact factor: 2.345